Loading stock data…
Alnylam Pharmaceuticals (ALNY)
$294.11+2.74 (+0.94%)
Market OpenUpdated 2:07 PM EDT
Alnylam Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alnylam Pharmaceuticals, Inc. in the Healthcare sector is trading at $291.37 with a market capitalization of $37.1B. Wall Street consensus targets $436.32 (25 analysts), implying a +49.7% move over the next 12 months. The stock is currently near its 52-week low of $273.11, remaining 21.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +49.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.17B↑ | $1.10B↓ | $1.25B↑ | $773.69M↑ | $594.19M |
| Gross Profit | $956.05M↑ | $829.31M↓ | $1.05B↑ | $630.74M↑ | $523.15M |
| Operating Income | $268.64M↑ | $131.72M↓ | $367.98M↑ | -$16.20M↓ | $18.08M |
| Net Income | $205.99M↑ | $186.42M↓ | $251.08M↑ | -$66.28M↓ | -$18.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
53.68%
Volume
Today's trading volume
637,330
Recent News
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 10, GENESIS Pharma said it expanded its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to include Denmark, Finland, Norway, and Sweden. It extension of a collaboration that began in Southeast Europe in 2019. […]
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most promising long-term stocks to buy according to analysts. On June 3, Alnylam and Inceptive Nucleics, which builds foundation models of life, announced a collaboration valued at up to $2 billion to accelerate the discovery of RNAi therapeutics. It combines Alnylam’s extensive RNAi platform and two decades […]
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to cover four Nordic countries, that is, Sweden, Finland, Denmark, and Norway. GENESIS is an Athens-based biopharma company and the expanded […]
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has entered a collaboration with Inceptive Nucleics to apply generative AI models to its RNAi research and development. The company has also expanded its commercial partnership with GENESIS Pharma to cover the Nordic countries, extending the reach of its RNAi therapies in Europe. Alnylam shares most recently closed at $282.85, with the stock down 29.3% year to date and down 8.2% over the past year. Over a 3 year period the stock is up 40.3%, and over...